Abstract 61P
Background
Cancer-associated fibroblasts (CAFs) are the most prominent stromal cells in the tumor microenvironment, playing a significant role in tumor progress. However, the specific mechanisms underlying CAF formation and their role in remodeling the tumor microenvironment remain unclear. Previous studies have demonstrated that tumor cell-released autophagosomes (TRAPs) can arrival to lung tissue and regulate the function of lung fibroblasts to form premetastatic niche.
Methods
Primary breast adipose fibroblasts (NFs) were obtained from fourth mammary fat pads of mice, and co-cultured with TRAPs for 48 hours. The chemokines in collected supernatant were measured by ELISA. The expression of PD-L1 on the surface of fibroblasts and the ability to inhibit T cells were measured by flow cytometry (FCM). DAMPs on the TRAP surface blocked by antibodies, and fibroblasts pretreated with inhibitors were used to detect the ligand receptors between TRAP and NFs. Mouse experiments were performed as follows: 1)Tumor-bearing mice were constructed using TRAP low-expression cell lines (Beclin1KD/Raba8a KD); 2) NFs and 4T1 cells, with or without TRAP stimulation, were mixed and implanted in mice to detect the proportion and function of various cells in the tumor microenvironment by FCM.
Results
In vitro experiments revealed that the proteins (HSP27/70) on the surface of TRAP bind to TLR4 on NFs, exerting their functions via the HSP27/70-TLR4-MyD88- NF-κB signal cascade, ultimately expressing higher levels of PD-L1. Compared to the normal control (NC) group, the proportion of neutrophils and monocytes in the tumor microenvironment decreased, opposite T cells increased. Furthermore, the ability of T cells to secrete IFN-γ partially recovered. The level of PD-L1 on the surface of fibroblasts decreased, and their ability to inhibit T cells weakened.
Conclusions
TRAPs induce the formation of inflammatory and immune-suppressive fibroblasts by secreting CXCL1/2 and CCL5 to attract neutrophils and monocytes to the tumor microenvironment. Additionally, TRAPs directly inhibit T cells, ultimately contributing to the formation of the tumor microenvironment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
X. Zhou, X. Wang, F. Zhu.
Funding
National Natural Science Foundation, China.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
497P - Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial
Presenter: Ying Jin
Session: Poster Display
Resources:
Abstract
498P - Frailty-adjusted life expectancy and survival in older lung cancer patients: A large-scale electronic health-record based study
Presenter: Thao Tu
Session: Poster Display
Resources:
Abstract
499P - Long-term survival and treatment (tx) patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC): Japanese cohort of a global real-world (rw) observational study
Presenter: Daichi Fujimoto
Session: Poster Display
Resources:
Abstract
500P - The effectiveness and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer: Real-world, multicenter, observational study (NEJ056)
Presenter: Hidehito Horinouchi
Session: Poster Display
Resources:
Abstract
501P - One-year survival outcomes of unresectable stage III non-small cell lung cancer patients who underwent PD-1 inhibitor plus chemo as induction therapy
Presenter: Xin Wang
Session: Poster Display
Resources:
Abstract
502P - Impact of sarcopenia on the outcome of patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
Presenter: Kentaro Tamura
Session: Poster Display
Resources:
Abstract
503P - Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with locally advanced NSCLC
Presenter: TSUYOSHI HIRATA
Session: Poster Display
Resources:
Abstract
504P - Real-world outcomes with induction systemic therapy for stage III in eligible for upfront local therapy: Pre vs post immunotherapy era in a tertiary referral centre
Presenter: Praveen Kumar Marimuthu
Session: Poster Display
Resources:
Abstract
505P - Neoadjuvant PD-1 inhibitor (tislelizumab) plus platinum–etoposide in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Junjie Hu
Session: Poster Display
Resources:
Abstract
506P - Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: Implications for thoracic radiotherapy
Presenter: Byoung Hyuck Kim
Session: Poster Display
Resources:
Abstract